A 2-year Follow-up Study to Assess Cognition and Health-related Quality of Life in Participants With Highly-active Relapsing Multiple Sclerosis, Having Participated in the CLARIFY MS Trial (CLARIFY MS Extension)
Latest Information Update: 27 May 2025
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLARIFY MS Extension
- Sponsors Merck KGaA
Most Recent Events
- 12 Sep 2023 Status changed from active, no longer recruiting to completed.
- 29 Aug 2023 This trial has been completed in Austria (global end date: 2023-06-20), according to European Clinical Trials Database record.
- 24 Aug 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.